Oryzon Genomics S.A. Total Current Liabilities

Oryzon Genomics S.A.'s total current liabilities stands at $11M as of June 2026. That compares with $13M in the prior-year period — down 17.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Oryzon Genomics S.A. reported $11M in total current liabilities versus $13M a year earlier — a 17.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $13M in the prior-year period — down 17.8% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Oryzon Genomics S.A.'s total current liabilities evolved across reporting periods, while the comparison chart places ORY.MC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Oryzon Genomics S.A.'s reading of $11M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.